UK's NHS claims CVD reduction target met

25 February 2008

The UK's public health care provider has claimed "outstanding progress" in the management of cardiovascular disease, based on two simultaneously-published reports. The Department of Health credits a range of measures, including the prescribing of statins, for meeting National Health Service targets in treating CVD five years ahead of schedule.

The National Service Framework for Coronary Heart Disease, which was formulated in March 2000, had set a 10-year deadline for reducing the mortality rate in people under 75 years by 40%. According to the newly-published CHD National Service Framework Progress Report, prescribing of statins has "more than doubled over the last three years, cutting both mortality from CHD and the yearly number of heart attacks."

The progress report notes that other factors were also responsible for the health outcomes improvements. For example, thrombolysis was provided in almost 70% of cases within an hour of an emergency call in late 2006, compared with just 24% in early 2001. The report also states that, "no patients are waiting over three months for heart surgery compared with over 5,000 in 2000."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight